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Effects of halofenate and probenecid on serum lipids and 
uric acid in hyperlipidemic, hyperuricemic adults 
The effect of halofenate was compared with that of probenecid in overweight patients with 
hyperlipidemia and hyperuricemia. Halofenate induced a prompt and sustained lowering 
( 12.7%) of serum triglycerides, but probenecid induced no change in serum triglycerides. 
Both drugs promptly induced reductions (32%) of serum uric acid. Halofenate induced a 
13.3 % increase in serum lactic dehydrogenase. Both drugs induced mild but significant 
decreases in hemoglobin and in serum albumin, but the between-group differences were 
not significant. When the effects of the two drugs were divided into subgroups below and 
above the baseline median value for serum triglycerides, cholesterol, uric acid, and 
percent ideal body weight, a differential effect on serum triglycerides was noted when 
serum uric acid and percent ideal body weight were taken as the segregating variables. 
There was a greater serum triglyceride decline after halofenate in the high-weight group 
than in the lower-weight group (-25.5% vs +2.7%), and a greater serum triglyceride 
decline in the high uric acid group than in the lower uric acid group (-22 .6% vs 
-2.4%). The divergent behavior in regard to initial percent ideal body weight and uric 
acid level may account for the greater halofenate-induced reductions in serum 
triglycerides reported by others. In the halofenate group, there was a significant 
correlation between percent change in triglycerides and percent calories from alcohol. 
Further study of these responses may provide increased understanding of halofenate 
action and of the pathogenesis of some types of hyperlipidemia. 
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Halofenate, 2-aceto amidoethyl (p-chloro-
phenyl) (m-triftuoromethylphenoxy) acetate, is 
an investigational hypoJipidemic drug which 
has also been demonstrated to be an ef-
fective uricosuric agent. Our study was de-
signed to compare the effects of halofenate and 
probenecid on serum lipid and uric acid values 
and on certain monitoring parameters in adults 
with hyperlipidemia and uricemia. We also 
sought to determine whether halofenate and 
probenecid induced different responses in 
serum cholesterol, triglycerides and uric acid in 
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Fig. 1. Effect of halofenate and probenecid on se-
rum triglycerides (mean ± SE). Baseline period: wk 
o to 8. 
patients with baseline levels of cholesterol, tri-
glycerides, uric acid and percent ideal body 
weight above the median value for the group 
and in patients with baseline levels for these 
parameters below the median value for the 
group. 
Materials and methods 
Patients between the ages of 21 and 65 yr 
were selected on the basis of elevation of both 
serum uric acid (7 mg/ I 00 ml or over for men 
and 6 mg/ 100 ml or over for women) and serum 
lipids (mean untreated serum cholesterol of 275 
mg/ I 00 ml or over and/or mean untreated fast-
ing serum triglycerides of 150 mg/100 ml or 
over) and their ability to participate in a 56-wk 
study. The following led to exclusion from the 
study: pregnancy, lactation, a history of uric 
acid renal stone formation, gouty nephropathy, 
requirement for long-term salicylate therapy, 
serious alcoholism, significant impairment of 
liver or renal function, recent severe or poorly 
controlled cardiac disease, any severe disease, 
and a history of significant prior adverse reac-
tion to probenecid or halofenate. 
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Fig. 2. Effect of halofenate and probenecid on serum 
cholesterol (mean ± SE). Baseline period: wk 0 to 8. 
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Fig. 3. Effect of haIofenate and probenecid on serum 
uric acid (mean ± SE). Baseline period: wk 0 to 8. 
Drug therapy was preceded by a control 
period of 8 wk during which patients were seen 
at 2-wk intervals and baseline clinical and lab-
oratory data were obtained. All patients had 
careful ophthalmologic examinations during the 
control period and again after 48 wk of treat-
ment. 
Patients were separated into four diagnostic 
categories as follows: (I) patients under 55 yr 
without clinical evidence of atherosclerosis; (2) 
patients under 55 yr with atherosclerotic compli· 
cations; (3) patients 55 yr and over with no 
atherosclerotic complications; (4) patients 55 yr 
and over with atherosclerotic complications. 
Twenty-six patients who met the criteria for 
entry into the study were randomly assigned to 
receive either halofenate or probenecid. The 
drugs were supplied as identical-appearing 
500-mg tablets. Dosage was based on the pa-
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Table I. Details of patients studied 
Patient 
Serial Age Height 
No. (yr) Sex Race (in) 
Halofenate group 
1. 1048 52 M W 70 
2. 1051 52 F W 65 
3. 1052 48 M W 68 
4. 1062 50 M W 63 
5. 1064 46 M W 71 
6. 1080 43 M W 69 
7. 1083 29 M W 69 
8.2010 43 F W 62 
9.2013 48 M W 68 
10. 3045 54 M W 72 
11. 3050 58 M W 74 
12.4014 64 M W 69 
Mean 48.9 68.3 
±SE 2.5 3.7 
Probenecid group 
1. 1049 54 M W 67 
2. 1050 46 M W 69 
3. 1053 51 F W 66 
4. 1063 46 M B 69 
5. 1065 41 M W 68 
6. 1081 28 M W 74 
7. 1084 32 M W 75 
8.2011 45 M W 71 
9. 3044 61 M B 65 
10. 3051 56 M W 68 
II. 3052 56 M W 70 
12.4015 65 M W 65 
Mean 48.4 68.9 
±SE 3.2 0.9 
P value NSt NSt 
Serum 
uric 
Weight* % ideal acid* 
(Ib) weight* (mg/lOO ml) 
227 144 10.4 
173 132 6.5 
196 131 10.2 
163 125 10.2 
185 114 12.0 
188 123 8.5 
183 120 7.5 
142 119 6.8 
151 101 10.9 
199 120 8.5 
225 128 11.4 
186 122 10.1 
185.0 123.9 9.42 
1.0 3.4 0.21 
212 146 8.7 
167 109 9.2 
158 117 7.7 
235 155 12.3 
215 144 10.5 
204 116 8.9 
209 116 8.1 
207 127 9.5 
179 132 10.1 
191 128 9.5 
199 127 9.0 
131 96 9.2 
192.3 126.7 9.39 
3.8 4.6 0.14 
NSt NSt NSt 
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Fasting 
serum 
Serum trigly-
cholesterol * ceride* 
(mg/lOO ml) (mg/lOO ml) 
243 350 
276 223 
248 232 
210 628 
212 278 
219 329 
246 152 
317 327 
228 189 
177 185 
267 245 
284 314 
244.0 292.6 
4.7 15.0 
205 362 
179 184 
360 201 
208 294 
289 609 
257 193 
258 323 
366 405 
271 323 
239 307 
303 293 
237 179 
264.3 323.3 
7.1 15.7 
NSt NS:j: 
CHD: coronary heart disease; CV: cerebral vascular disease; PV: peripheral vascular disease; +: with disease; -: without disease. 
'Value: average of all baseline values. 
tStudent's t test, halofenate group vs probenecid group; NS: not significant (p > 0.05). 
:j:Student's t test performed on log serum triglyceride value; Mann-Whitney U test also NS. 
tient's actual weight as follows: under 60 kg, itors, and hypolipidemic drugs were not per-
500 mg once daily; 60 to 99 kg, 1,000 mg once mitted. Other medication needed for the pa-
daily; 100 kg and above, 1,500 mg once daily. tient's well-being were continued throughout 
Patients were seen 2 and 4 wk after the starting the study. Changes in such medication during 
of treatment and at 4-wk intervals thereafter. At the study were noted. No specific dietary regi-
each 4-wk visit they were required to return all men was prescribed, but an attempt was made 
unused medication. The tablets were counted to have each patient follow the same diet 
and recorded to document compliance to the throughout the study. Diet histories were ob-
prescribed schedule. Downward dosage ad- tained from most patients at the start and com-
justment was permitted in the event of minor pletion of the study. 
intolerance or side effects. At each visit, patients' weight, blood pres-
Uricosuric drugs, xanthine oxidase inhib- sure, pulse, liver size, and drug tolerance were 
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Clinically 
evident 
Lipopro- atherosclerosis 
teinemia 
I CV I PV 
Diabetes 
type * CHD Gout mellitus 
IV 
IV 
IV 
IV 
IV 
IV 
IV 
lIb 
IV 
IV 
IV 
IV 
IV 
IV 
lIb 
IV 
IV 
IV 
IV 
lIb 
IV 
IV 
IV 
IV 
+ 
+ 
+ 
+ + 
+ 
+ 
+ + 
+ + + 
+ + 
+ 
+ + 
+ 
+ 
+ + 
+ 
+ + 
+ 
+ 
+ 
+ Prob 
noted. Percent ideal weight was based on 
Metropolitan Life Insurance tables (taking mid-
point for medium frame).32 Laboratory evalua-
tions included appearance of fasting serum, 
fasting serum cholesterol,8 triglycerides,7 uric 
acid,1O and lipoprotein typing. 15 Hemoglobin, 
hematocrit, white blood cell count (WBC) and 
differential, platelet count, and urine were ana-
lyzed by standard techniques. Serum glucose, 
blood urea nitrogen, serum bilirubin, serum 
glutamic oxaloacetic transaminase (SOOT), 
(lactic dehydrogenase) (LDH) , serum alkaline 
phosphatase, creatine phosphokinase (CPK) , 
total serum protein, and serum albumin were 
determined by AutoAnalyzer (SMA 12-60),31 
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While 13 subjects began the study in each 
treatment group, one subject in the probenecid 
group left after 12 wk because of recurrent 
stomatitis possibly aggravated by probenecid 
and one in the halofenate group left after 4 wk 
because of fever, shaking chills, gingivitis, and 
marked neutropenia. He was hospitalized 
elsewhere and halofenate was discontinued; 
WBC returned to normal within 12 days. Re-
sults reported here are for the 24 patients who 
completed the 56-wk study. 
Results 
Baseline studies (intergroup comparisons). 
Table I presents the principal clinical charac-
teristics of the patients studied. A number of 
other clinical, hemodynamic, biochemical, 
hematologic, and other parameters measured 
were found not to be significantly affected. * 
Effects of halofenate in group H or pro-
benecid in group P (within-group studies). The 
effects of each drug and data for each visit dur-
ing the baseline period (wk 0 to 8) and for each 
visit during the treatment period (wk 10 to 56) 
were plotted. Figs. 1, 2, and 3 show mean 
(±SE of the mean) for serum triglycerides and 
percent ideal weight, serum cholesterol, and 
serum uric acid. 
To determine whether the drugs had sig-
nificant effects on serum triglycerides, cho-
lesterol, or uric acid or on biochemical, he-
matologic, or other parameters, baseline data 
were averaged. ("Baseline" will refer to the 
period of placebo administration, i.e., wk 0 to 
8.) The 48-wk treatment period was then arbi-
trarily divided into weeks 10 to 24 (period A), 
weeks 28 to 40 (period B), and weeks 44 to 56 
(period C). 
Table II indicates that there was a decline 
in serum triglycerides (11.7%) between the 
baseline period and period A in the group taking 
halofenate (group H). This decline was sus-
tained throughout the entire treatment period 
and averaged 12.7% for the entire period (p = 
'Summary of the various baseline parameters measured, and re-
sults found, are not printed here. They have been deposited in the 
permanent files of The C. V. Mosby Company. To obtain a photo. 
copy, please address your request to the Journal Permissions De-
partment, The C. V. Mosby Company, 11830 Westline Industrial 
Drive, SI. Louis, Mo. 63141. 
344 Bassett et al. Clinical Pharmacology 
and Therapeutics 
Table II. Changes observed in metabolic parameters in patients receiving halofenate or 
probenecid (intragroup comparisons by paired t test) 
Total 
Treatment periods*t treatment 
Baseline period 
period A B C A-C 
Parameter (0-8 wk) (10-24 wk) (28-40 wk) (44-56 wk) (10-56 wk) 
Halofenate group 
Serum triglycerides 292.6 258.3 (88.3) 253.6 (86.7) 252.9 (86.4) 255.5 (87.3) 
(mg/100 ml:j:) 
p value 0.04 
Serum cholesterol 244.0 243.4 (99.8) 247.9 (101.6) 250.3 ( 102.6) 246.9 (101.2) 
(mg/100 ml) 
p value NS§ 
Serum uric acid 9.42 6.47 (68.7) 6.10 (64.8) 6.14 (65.2) 6.25 (66.4) 
(mg/100 ml) 
p value <0.0001 
% ideal weight 123.9 125.6 (101.4) 126.7 (102.2) 127.8 (103.1) 126.6 ( 102.2) 
P value 0.04 
Probenecid group 
Serum triglycerides 323.3 308.7 (95.5) 332.4 (102.8) 356.9 (110.4) 330.7 (102.3) 
(mg/100 ml:j:) 
p value NS 
Serum cholesterol 264.3 252.8 (95.6) 260.6 (98.6) 259.0 (98.0) 257.1 (97.3) 
(mg/100 ml) 
p value NS 
Serum uric acid 9.39 6.62 (70.5) 6.61 (70.4) 6.48 (69.0) 6.57 (70.0) 
(mg/100 ml) 
p value <0.0001 
% ideal weight 126.7 126.3 (99.7) 127.9 ( 100.9) 128.5 (101.4) 127.5 ( 100.6) 
P value NS 
'Total treatment period was arbitrarily divided into three approximately equal time periods. Drug therapy remained the same throughout 
periods A. B. and C. 
tFigures in parentheses = % of baseline value. 
:j:Paired t tests were performed on log· transformed data. 
§NS: not significant; p > 0.05. 
0.04). (See below for analysis of factors re-
lating to the wide variability in individual tri-
glyceride responses in group H.) Halofenate did 
not induce a significant change in serum choles-
terol concentration but it did induce a decline in 
serum uric acid concentration of 31.3% in 
period A. This decline was sustained through-
out the remaining period, averaging 33.6% (p < 
0.0001). A mild gradual increase in weight was 
noted, reaching 3.1 % in period C and averaging 
2.2% for the entire treatment period (p = 
0.04). 
The effect of halofenate on various biochem-
ical, hematologic, and hemodynamic parame-
ters and its effect on ophthalmologic and elec-
trocardiographic status were tested with the use 
of paired t test analysis (or contingency table 
type of analysis in the case of categoric data). In 
patients receiving halofenate, significant reduc-
tions occurred (Table III) in the following pa-
rameters in one or more of periods A, B, and C: 
fasting serum glucose (average 8.7% reduc-
tion, periods A to C); total protein (2.9% de-
cline in period B); serum albumin (13.2% de-
cline, periods A to C); bilirubin (51% decline, 
periods A to C); hematocrit (3.0% decline in 
period C); hemoglobin (6.8% decline in periods 
B and C); systolic blood pressure (3.8% decline 
in period A); diastolic blood pressure (4.8% de-
cline in periods A to C). Serum LDH was 
significantly elevated (average of 13.3%) 
throughout the entire treatment period. There 
were no significant differences in the other 
biochemical or hematologic parameters or in 
Volume 22 
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Table III. Changes observed in biochemical, hematologic, and hemodynamic parameters in 
patients receiving halofenate or probenecid (intragroup comparisons) 
Total 
Treatment periods treatment 
Baseline l 
period, 
period A B C A-C 
Parameter (0-8 wk) (10-24 wk) (28-40 wk) (44-56 wk) (l0-56 wk) 
Halofenate group 
Fasting serum glucose 122.2 110.7 (90.6) 106.4 (87.1) 116.0 (94.9) 111.6 (91.3) 
(mg/IOO ml) 
p value 0.009 
Serum protein 7.35 7.31 (99.5) 7.14 (97.1) 7.23 (98.4) 7.26 (98.8) 
(gm/IOO ml) 
p value NS 
Serum albumin 4.47 3.98 (89.0) 3.80 (85.0) 3.73 (83.4) 3.88 (86.8) 
(gm/IOO ml) 
p value <0.0001 
Serum bilirubin 1.00 0.50 (50) 0.48 (48) 0.48 (48) 0.49 (49) 
(mg/IOO ml) 
p value 0.008 
Serum LDH (IU) 169.3 193.9 ( 114.5) 187.2 (110.6) 189.8 (112.1) 191.8 (113.3) 
P value 0.0003 
Hematocrit (%) 46.7 45.8 (98.1) 45.7 (97.9) 45.3 (97.0) 45.6 (97.6) 
p value 0.03 
Hemoglobin (gm/ 100 ml) 16.2 16.3 (100.6) 15.1 (93.2) 15.1 (93.2) 15.8 (97.5) 
p value NS 
Systolic blood pressure 137.0 131.8 (96.2) 132.8 (96.9) 131.7 (96.1) 132.2 (96.5) 
(mm Hg) 
p value NS 
Diastolic blood pressure 87.6 84.2 (96.1) 83.2 (95.0) 82.4 (94.1) 83.4 (95.2) 
(mm Hg) 
p value 0.03 
Probenecid group 
Serum albumin 4.29 4.06 (94.6) 3.98 (92.8) 3.77 (87.9) 3.97 (92.5) 
(gm/ 100 ml) 
p value 0.0009 
Hemoglobin (gm/ 100 ml) 16.5 16.1 (97.6) 15.8 (95.8) 15.7 (95.2) 15.9 (96.4) 
P value NS 
Systolic blood pressure 144.2 141.4 (98.1 ) 140.1 (97.2) 140.8 (97.6) 140.8 (97.6) 
(mm Hg) 
p value NS 
Diastolic blood pressure 95.0 93.6 (98.5) 91.8 (96.6) 91.2 (96.0) 92.3 (97.2) 
(mm Hg) 
p value 0.05 
Figures in parentheses = % of baseline value; p value is for baseline value vs period A to C value by paired t test. 
the ophthalmologic and electrocardiographic 
findings. 
In the probenecid group there were no 
significant changes in ideal weight or in serum 
triglycerides or cholesterol. As expected, pro-
benecid induced a prompt decline in serum uric 
acid in period A which was sustained through-
out periods Band C, averaging 30% for the 
entire treatment period (p < 0.0001). 
In the patients receiving probenecid, there 
were significant reductions (Table III) in serum 
albumin (7.5% decline, periods A to C), hemo-
globin (4.5% decline, periods B and C), and 
systolic and diastolic blood pressure (3% de-
cline in period B). There were no significant 
differences in the other biochemical or hema-
tologic parameters or in the ophthalmologic 
and electrocardiographic parameters. 
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Aside from leukopenia in one patient on 
halofenate and stomatitis in one patient on 
probenecid described above, there were no 
significant adverse effects during the study. 
Comparison of the effects of halofenate 
and probenecid on certain parameters (be-
tween-group comparisons), To determine 
whether halofenate and probenecid exerted 
significantly different effects on serum triglyc-
erides, cholesterol, and uric acid, the analytic 
approach involved a one-way analysis of co-
variance with one covariate. In this approach, 
the mean levels of triglycerides, cholesterol, 
uric acid, and percent ideal weight for each sub-
ject were computed for the baseline period and 
period C. The difference between the two time 
periods for each parameter was computed, pro-
ducing new variables: Ll triglycerides (Ll TG), Ll 
cholesterol (LlCH), Ll uric acid (LlUA), and Ll 
percent ideal weight (Ll %IW), respectively. 
Because changes in percent ideal weight over 
time might affect serum triglyceride, 6 choles-
terol,41 or uric acid,35 one-way analysis of 
covariance was performed with the use of Ll TG 
(or LlCH, or LlUA) as the dependent variable, 
Ll%IW as the covariate, and the drug type as the 
factor to be considered. In other words, the 
change in serum triglyceride, cholesterol, or 
uric acid concentration (LlTG, LlCH, LlUA) 
from baseline period to period C is compared, 
adjusting for possible changes in percent ideal 
weight between the same two time periods and 
testing whether the changes with halofenate 
were significantly different from those with 
probenecid. 
These analyses revealed that there was no 
significant difference between halofenate and 
probenecid in their effects on serum cholesterol 
or uric acid in the two groups. There was, how-
ever, a significant difference (p = 0.006) in the 
case of serum triglycerides, with the halofenate 
group exhibiting lower values. 
The same analytic approach was next 
adopted to determine whether intergroup differ-
ences in serum triglyceride concentration were 
noted between baseline and period A and 
baseline and period B and between periods A 
and B, A and C, and Band C. There were no 
significant differences in the effects of halofe-
nate and probenecid in any of these shorter time 
Clinical Pharmacology 
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period comparisons. Thus it appears that the 
difference in the effect of the two drugs on 
serum triglycerides becomes more marked with 
time, reaching statistical significance in 44 to 
56 wk of treatment. Both drugs reduced the 
level of serum triglycerides initially, but the 
halofenate group maintained this reduced level 
while the serum triglycerides in the probenecid 
group rose above baseline after period A. 
Comparison of halofenate with pro-
benecid: Effects on other parameters (be-
tween-group comparisons), With the use of 
the same approach, analyses were conducted 
to compare the effects of halofenate and pro-
benecid on those other biochemical, he-
matologic, and hemodynamic parameters de-
scribed above in which inspection of the 
within-group mean values for each parameter 
followed over time suggested the possibility of 
differential effect. 
Analyzing the effects on serum LDH, the 
mean difference (baseline to period C) for 
group H was 20.5 IU (12.1% increase), while 
that for the probenecid group (group P) de-
creased 34.4 IU «p = 0.0005) with Mann-
Whitney U test, since the data were skewed). 
With the use of the same approach, between-
group comparisons of fasting serum glucose, 
total protein, albumin, bilirubin, hematocrit, 
hemoglobin, and systolic and diastolic blood 
pressure revealed no statistically significant dif-
ferences. 
Relationship of initial serum lipid, uric 
acid, or percent ideal weight level to sub-
sequent responses to drug therapy (be-
tween-group analyses), To determine wheth-
er the drug effect on serum triglycerides, 
cholesterol, or uric acid might be a function of 
the initial level of these variables (or of per-
cent ideal weight), the effects of halofenate 
and probenecid were compared. The median 
baseline levels (within groups Hand P sepa-
rately) of serum triglycerides, cholesterol, uric 
acid, and percent ideal weight were determined, 
and then, within each drug group, each indi-
vidual was assigned to either the high or the low 
stratum. Finally, a series of two-way analyses 
of covariance were performed on the dependent 
variables LlTG, LlCH, and LlUA with one 
covariate (Ll%IW) and two factors (level = 
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high or low and drug type = H or P). These 
analyses* revealed: (1) the expected "drug ef-
fect" due to halofenate (Table II) when the re-
sponse variable was serum triglycerides and 
baseline was compared with period C; (2) a dif-
ferential high-low effect was noted when the 
variable was serum uric acid and again when 
the variable was percent ideal weight. In the 
former, a differential response was noted in two 
response variables (serum triglycerides and uric 
acid), while in the latter a differential response 
was noted only in serum triglycerides. These 
responses were evident when baseline and 
period C data were compared and also when 
baseline data were compared with all treatment 
periods combined. In all cases, there was a 
greater effect (a greater decline) in the "high" 
halofenate group than in the "low" halofenate 
group. Likewise, there was a greater decline (or 
a lesser increase) in the "high" probenecid 
group than in the "low" probenecid group. 
This was noted when both uric acid and percent 
ideal weight were the segregating variables. 
The greatest difference in halofenate effect was 
noted when percent ideal weight was the seg-
regating variable; in the baseline/period C 
comparison, the "high" halofenate group expe-
rienced a 25.5% decline in serum triglycerides, 
whereas in the "low" halofenate group there 
was a 2.7% rise in serum triglycerides. When 
the halofenate group was segregated on baseline 
serum uric acid level, there was a 22.6% reduc-
tion in the "high" group, whereas there was a 
2.4% reduction in serum triglycerides in the 
"low" group between baseline and period C. 
Relationship of certain dietary and disease 
variables to percent change in triglycerides 
and percent change in ideal body weight (in-
tragroup comparisons), Because the average 
percent reduction in serum triglycerides in 
group H was considerably less than that re-
ported by others and because of the wide varia-
bility in the Il TO (baseline to period C; 
range = -48.3 % to + 34.1 %), certain other 
variables which might also affect serum tri-
glyceride level were examined by scatter plots 
and analysis of correlation coefficients. In 
* A table summarizing these results is filed in the permanent files 
of The C. V. Mosby Company. See footnote on page 343. 
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group H, there was a correlation between 
%IlTO and % calories from alcohol; in group P 
there was a correlation between %IlTO and 
%IlIW (p < 0.05 for both).* 
Discussion 
Others have reported l - 5 , 9, 17, 21-22, 24, 26, 29, 
31, 33, 36, 38-40, 46, 47 that the principal clinically 
significant effects of halofenate were on fasting 
serum triglyceride and uric acid concentrations. 
In our study, the halofenate group averaged a 
12.7% decline in serum triglycerides (range, 
-48.3% to +34.1%) which was evident within 
2 wk and sustained over 48 wk. The decline 
in serum triglycerides was generally dependent 
(though not in a linear fashion) on the initial 
percent ideal body weight and the initial serum 
uric acid level. It was not significantly related to 
the initial serum triglyceride or to cholesterol 
concentration. While careful efforts were made 
to assure constant weight in subjects throughout 
the study and while the average weights re-
mained wi thin ± 10 pounds of starting weight in 
87% of subjects, even this weight change had 
an effect on the triglyceride values. Analysis of 
individualll TO values revealed a significant re-
lationship to change in weight in group P but 
not in group H (suggesting that the effect of 
halofenate overrides the expected relationship 
between Il TO and IlIW) and in group H to per-
cent alcohol intake in baseline. 
Halofenate induced a 31 % decline in serum 
uric acid which was evident within 2 wk and 
sustained over the entire treatment period. The 
uric acid effect was essentially identical to that 
achieved with probenecid. Other studies22, 24, 33, 
36, 46 have demonstrated that the decline in 
serum uric acid concentration results from the 
uricosuric effect of halofenate. Our study indi-
cates that the degree of reduction in serum uric 
acid with both halofenate and probenecid is re-
lated to the initial serum uric acid concentration 
and in the probenecid group also correlates with 
the baseline percent ideal weight. 
Halofenate induced a transitory decline in 
serum cholesterol (6.0%) at 2 wk, followed by 
* A more detailed description of these analyses is filed in the 
permanent files of The C. V. Mosby Company. See footnote on 
page 343. 
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an immediate return to baseline resulting in no 
significant overall effect. 
Changes were noted (on intragroup analy-
sis) in the halofenate group in fasting serum 
glucose, protein, albumin, bilirubin, hemato-
crit, hemoglobin, systolic and diastolic blood 
pressures (declines), and serum LDH (eleva-
tion) and in the probenecid group in serum al-
bumin, hemoglobin, and systolic and diastolic 
blood pressures (declines). When intergroup 
comparisons were performed, the only sig-
nificant difference was in serum LDH (with 
halofenate producing a greater percent in-
crease). 
The reduction of serum glucose by halofenate 
was shown not to be related to the taking of 
sulfonylurea drugs by patients in the halofenate 
group.25 (Only one subject was taking tol-
butamide; exclusion of data on the subject did 
not materially alter the serum glucose re-
sponses.) The lowered serum glucose may re-
sult from a reduced insulin/glucagon ratio.13 
The lowering of serum bilirubin concentra-
tion in the halofenate group already reported by 
others21. 22. 33. 40 was of similar magnitude and 
is considered to be due to the vigorous binding 
of halofenate to albuminl2 . 14, 20. 42, 43, 45 which 
in tum decreases the binding of organic com-
pounds such as bilirubin,23. 44, 48 resulting in 
increased bilirubin clearance and decreased 
serum bilirubin concentration. 
The effect of halofenate on serum protein and 
albumin concentrations may be due to its effect 
in reducing amino acid incorporation into pro-
tein, as shown by Homcy and Margolis19 with 
the use of 14C-Ieucine incorporation. This effect 
does not appear to be explicable entirely by 
hemodilution, since the hemoglobin concentra-
tion with halofenate was slightly higher than 
that with probenecid, but in view of the lower-
ing of hemoglobin observed in both treatment 
groups a contributory role of hemodilution is 
not ruled out. Support for hemodilution as a 
factor is the finding that in diabetes insipidus 
halofenate has an antidiuretic effect16 similar to 
that of clofibrate. 34 
In our study, there was a small increase in 
percent ideal body weight in the halofenate 
group, rising in the final 12 wk of therapy to 
3.1% above control and averaging 2.2% over 
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the entire 48-wk treatment period. These weight 
changes did not differ significantly from the 
weight gain in the probenecid group. When the 
values for the 2 subjects (one diabetic) who 
gained more than 5% of ideal weight in the 
halofenate group are excluded, the percent 
change averaged + 1.4. When the values for 
the 2 subjects (one diabetic) who gained more 
than 5% ideal weight in the probenecid group 
are excluded, the percent change averaged 
-0.7. 
An increase in body weight has been reported 
in outpatients taking clofibrate,l1 which has 
been shown not to be due to fluid retention30 
and is postulated30 to represent increased 
adipose tissue mass. More study involving re-
peated assessment of caloric intake and energy 
expenditure and measurement of percent adi-
pose mass is required to resolve the question 
whether and how halofenate induces weight 
gain in subjects at isocaloric status. 
Only Morgan and co-workers33 and Hutchin-
son and Wilkinson2 1. 22 have reported on the 
effect of halofenate on LDH responses. They 
found, contrary to our detection of a significant 
elevation (13.3% for all study periods com-
bined), that it did not change. LDH is found in 
all tissues, especially in myocardium, kidney, 
liver, and muscle. The mechanism for the ob-
served increase is not yet known. Others have 
reported elevations in SOOP· 2, 4 and serum 
CPK.l, 2, 4, 21 Whether these changes represent 
hepatic, muscle, or other tissue response is not 
yet known. 
In an attempt to determine why the average 
percent reduction in serum triglyceride concen-
tration is smaller in this study than in many 
others, all relevant studies were reviewed and 
results tabulated to enable comparison of 
studies of the multiple factors. Because changes 
in weight can produce changes in serum triglyc-
erides,6 cholesterol ,41 or uric acid,35 valid com-
parisons were possible only in studies which 
indicated whether weight changes occurred. 
Only four studies22, 29, 33, 36 indicated the weight 
status at the end of the study (all stated that 
there had been no weight change), but no values 
for weight at the close of study are given and 
none indicate the subject's degree of over-
weight. In these studies, all administered 1.0 
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gm/day halofenate. The duration of studies and 
the percent decline in serum triglycerides were: 
Morgan and associates,33 6 wk, 50% decrease; 
Ravenscroft and co-workers,36 9 days, 26% de-
crease; Hutchinson and colleagues,22 4 wk, 
16% decrease (reported, ". . . no significant 
change in triglycerides due to wide range of 
values"); Lisch and associates,29 48 wk, 47% 
decline during the second 24-wk period in 6 
type IV patients. Statistical analysis29 was done 
by means of Student's t test, with "treatment 
period results" compared with baseline. It is 
unclear whether a paired t test was used, and no 
allowance appears to have been made for the 
skewed triglyceride distribution. Nevertheless, 
the graphic presentation of the mean data ap-
pears significant. Our findings (see "Results" 
section) are likely to reveal the principal rea-
sons for the differences reported in various 
studies, i.e., the importance of the percent ideal 
weight, serum uric acid, and alcohol intake in 
determining the degree of triglyceride reduc-
tion. 
Only a few studies have been published 
which describe mechanisms by which halofe-
nate might lower serum triglyceride concen-
trations. Homcy and Margolis19 reported on the 
comparative effects of halofenate and clofibrate 
on acetate and fatty acid oxidation and on lipid 
and protein synthesis in isolated rat hepato-
cytes. Halofenate was 30 times as potent in de-
creasing lipid synthesis from 14C-acetate; it also 
inhibited 14C-leucine incorporation into protein. 
These workers proposed, based on earlier 
work,12, 14, 20, 42, 43, 45 that displacement by the 
drug of fatty acid from albumin was responsible 
for its principal effects. Greenspan and associ-
ates18 compared the effects of halofenate and 
clofibrate on lipid synthesis in isolated rat 
adipocytes and found these drugs to inhibit the 
incorporation of tagged glucose and pyruvate 
into adipose fatty acids. The strong tendency 
for halofenate to bind to albumin appears to be 
the basis, and possibly the sole basis, for the 
effects of halofenate noted in relation to thyroid 
hormone and related compounds,12 bilirubin2 1. 
22, 33, 40 and sulfonylureas. 25 Additional reac-
tions which must be considered in the use of 
halofenate as a pharmacotherapeutic agent in-
clude the significance of its effect on serum 
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CPK, SGOT, and LDH, the mechanisms of its 
decreased beta blockade effect, 28 and the 
mechanism of its effect in decreasing platelet 
aggregation. 27 
The principal contribution of our work is the 
demonstration of the relationship of initial per-
cent ideal body weight to subsequent response 
in serum triglyceride concentration to halofe-
nate and probenecid, and the relationship of ini-
tial serum uric acid concentration to subsequent 
serum triglyceride and uric acid response to 
halofenate and probenecid. The approach taken 
here is one way of considering the law of the 
initial value. 49 Workers undertaking similar 
studies of the effects of this or similar drugs 
should carefully evaluate the degree of over-
weight and of relative adipose mass and should 
assure that weight is kept constant and is re-
ported in such studies. Analyses should be 
made of drug dosage, caloric intake, nutrient 
intake, and energy expenditure and their effects 
on serum lipids and uric acid. Only when this is 
done will it be possible to draw firm conclu-
sions on the effectiveness of halofenate (or of 
any drug) in hyperlipidemic or hyperuricemic 
patients. 
We gratefull y acknowledge Marlene J. Winchester 
for office management relating to study, Beverly M. 
Steinke for coordination of patient scheduling and 
data recording, George Kunkel, M.D., for clinical 
evaluation of some patients, C. J. Davis, M.D., for 
ophthalmologic examinations, K. John Jarrett, 
M.P.H., for serum lipid analyses, Joan E. Himes for 
uric acid analyses, and William H. Mikkelsen for 
coding and initial processing of data. 
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